ArticleJournal of Korean medical science2019
Chordomas: Histopathological Study in View of Anatomical Location.
Article in Journal of Korean medical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recurrent Dedifferentiated Clival Chondrosarcoma Presenting 32 Years after Initial Treatment: A Case Report.Journal of neurological surgery reports · 2026Article
- From Histology to Multi-Omics: Review of Chordoma Classification and Its Clinical Implications.Cells · 2026Review
- Sacral chordomas: surgical management, reconstruction, and translational advances: a systematic review.Journal of spine surgery (Hong Kong) · 2026Review
- Correlation Between Molecular Genetic Analysis and Nuclear Pleomorphism in Long-Term Recurrent and Metastatic Chordoma.Cancers · 2026Article
- Combining morphological and functional imaging parameters to diagnose primary bone neoplasms in the skull base, spine and sacrum.Skeletal radiology · 2025Article
- Surgical management of skull base and spinal chordomas: A case series with comprehensive review of the literature.North American Spine Society journal · 2024Article
- Research hotspots and trends of chordoma: A bibliometric analysis.Frontiers in oncology · 2022Article
- Radiotherapy of extraosseous nasopharyngeal chordoma: A case report and literature review.Molecular and clinical oncology · 2021Article
- A rare case of chordoma presenting as a Pancoast tumor.Rare tumors · 2021Article
- Results following surgical resection of recurrent chordoma of the spine: experience in a single institution.World journal of surgical oncology · 2020Article
- Clival chordoma in a young male patient: a case report.The Pan African medical journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChordomas are aggressive bone tumors that have a predilection for the axial skeleton including the skull base and spinal/sacral bones. However, the histopathological and clinical differences between skull base chordoma (SBC) and sacral/spinal chordoma (SC) are unclear as previous studies have been focused on patient prognosis and treatment outcome. This study aimed to evaluate the clinicopathologic features and prognosis of chordoma according to its location.
methodsPatients with chordomas were enrolled, and the histopathologic features were compared according to the tumor location.
resultsA total of 52 patients were enrolled. SBCs had more abundant chondroid matrix and diffuse growth pattern, while SCs had non-chondroid, myxoid matrix and a lobulating pattern, typical of chordoma. Old age and residual tumors were risk factors for shorter overall survival in SBCs. The chondroid matrix was an independent risk factor for shorter disease-free survival in the overall population.
conclusionChordomas have different histopathologic features depending on the anatomical location.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.